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Abstract The pET(scF11) plasmid was constructed comprising
the gene of a single-chain antibody against human ferritin. This
plasmid encodes the leader peptide pelB followed by the heavy
chain variable VH domain, (Gly4Ser)3 linker peptide, and light
chain variable VL domain. The correctly processed scF11
antibody was expressed in Escherichia coli as an insoluble
protein without the leader peptide. Purified soluble scF11 was
obtained after solubilization in 6 M GdnHCl followed by a
sequential dialysis against decreasing urea concentrations and
ion-exchange chromatography. ScF11 demonstrated only aV8-
fold decrease in the affinity (Ka = 5.1U10
8 M31 in RIA and
1.8U108 M31 in ELISA) vs. the parent IgG2a/U monoclonal
antibody F11. The emission maximum of intrinsic fluorescence
strongly suggests a compact conformation with tryptophanyl
fluorophores buried in the protein interior, consistent with the
functionality of the protein. However, scF11 demonstrated (i) the
lack of denaturant-induced fluorescence ‘dequenching’ effect
characteristic of the completely folded parent antibody, and (ii)
prominent binding, under physiological conditions, of a hydro-
phobic probe 8-anilino-1-naphthalenesulfonate (ANS) recogniz-
ing partially structured states of a protein. These findings are
indicative of an incomplete tertiary fold that gives ANS access to
the protein hydrophobic core. This work provides the first
indication that the functional single-chain antibody scF11
displays some properties of a partially structured state and
therefore may possess incomplete folding.
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1. Introduction
Single-chain antibodies, also referred to as scFv proteins,
comprise variable domains fused by a linker peptide resulting
in the VH-linker-VL or VL-linker-VH constructs [1,2]. Since
introduction of these recombinant antibodies, there has been
growing use of scFv proteins as reagents for therapy, diag-
nostics, and biomedical research. Large-scale production of
scFv proteins generally yields insoluble protein aggregates
which can be converted to a soluble functional state by
the procedure comprising solubilization with GdnHCl and
subsequent refolding on removal of the denaturant (see [3,4]
for examples). Based on the functionality of scFv proteins,
it was generally concluded that they possess the native
immunoglobulin fold. However, in comparison with native
immunoglobulins and their fragments, single-chain antibodies
have lower long-term stability and higher tendency for aggre-
gation [3,5^8]. These observations, which are easier to recon-
cile with the model of a partially folded rather than com-
pletely folded protein, can be considered as an indirect
indication of non-native folding of single-chain antibodies.
Therefore, it seemed reasonable to study the conformation
of an scFv protein using a probe recognizing partially struc-
tured protein states.
Hydrophobic dye 8-anilino-1-naphthalenesulfonate (ANS)
is the generally accepted probe for proteins with incom-
plete folding. This probe does not bind to fully folded proteins
nor does it interact with completely unfolded polypeptides,
but demonstrates pronounced binding to compact par-
tially structured states [9]. Therefore, ANS binding is consid-
ered as a reliable indication of a partially disordered three-
dimensional structure with £uctuating tertiary interactions
allowing the dye to access the hydrophobic core of a protein
[10].
In this work, we describe the construction, expression
and refolding of the puri¢ed single-chain antibody scF11
against human ferritin. Ferritin is a tumor-associated marker
for human hepatocellular carcinoma [11], myeloid leukemia
and Hodgkin’s disease [12,13], and head and neck squamous
cell carcinoma [14]. Radiolabeled full-length antibodies to
human ferritin were successfully used for therapy of in-
operable liver carcinoma and Hodgkin’s disease [15]. Pro-
duced in E. coli in preparative amounts and refolded, the
soluble scF11 antibody exhibited a compact and functional
conformation which possessed aromatic £uorophores buried
in the protein interior. Some folding-related properties of
scF11, such as binding activity, solubility, stability, and
apparently two-state denaturant-induced unfolding, were
similar to those reported for other scFv proteins, except
for ANS-binding capacity which was not previously con-
sidered. We found that the scF11 antibody demonstrated
prominent ANS-binding capacity similar to that of partial-
ly structured states. This work provides the ¢rst indication
that a functional scFv protein displays some properties of a
partially structured state and therefore may possess incom-
plete folding.
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2. Materials and methods
2.1. Enzymes and reagents
Restriction enzymes, Thermus aquaticus DNA polymerase, and T7
DNA polymerase were purchased from Fermantas (Lithuania); T4
DNA ligase, E. coli DNA polymerase I Klenow fragment, reagent
kits for nick-translation, cDNA synthesis, 5P- and 3P-terminal DNA
labeling were from Amersham (UK); the reagent kit for PCR was
from Perkin Elmer-Cetus (USA), and nutrient media components
from Difco (USA). PCR primers CAGGTGCAGCTGAAGCAG,
TGAGGAGACTGTGAGTGG, GACATCCAGATGACACAG,
CCGTTTTATTTCCAACT, TGACCACACTCCCCTTGGT, GGC-
CATCGCTGGTTGGGC, GGATCCGCCGCCACCAG were or-
dered by Fermentas (Lithuania). Labeled reagents: [32P]dATP,
[32P]dCTP, and [33P]dATP were purchased from the State Institute
of Applied Chemistry (GIPKh, St. Petersburg, Russia). Streptavidin
and its conjugate with horseradish peroxidase, PMSF, isopropyl L-D-
thiogalactopyranoside, 8-anilino-1-naphthalenesulfonate, guanidine
hydrochloride, and bovine serum albumin were from Sigma (USA),
and Iodogen was from Pierce (USA). The protein molecular mass
markers were from Serva (Germany).
2.2. Bacterial strains
DH 5K (F3, v(lacZYAargF)U169, recA1, endA1, hsdR17, (r-k,
m+k), supE44, x80dlacZvM15, gyrA96, relA1, deoR, thi-1), BL21
(DE3) (F3, ompT, rb, mb, V lysogen containing T7 RNA polymerase
under control of lacUV5 promoter).
2.3. DNA cloning procedures
Standard molecular biology techniques were used for constructing
the scF11 encoding plasmid [16]. Brie£y, DNA fragments were iso-
lated by electroelution into a dialysis sac, and puri¢ed by chromatog-
raphy on NENSORB 20 (NEN-DuPont, USA). Poly(A) RNA was
isolated from 2U107 hybriboma F11 cells producing mouse IgG2a/U
antiferritin antibody and cDNA was synthesized using a random mix-
ture of hexadeoxyribonucleotide primers [16]. Double-stranded cDNA
was inserted into pBR322 and the library in E. coli was analyzed using
probes for mouse Q1 [17] and U [18] immunoglobulin genes. The iso-
lated heavy and light chain genes of the F11 antibody were sequenced
and used for engineering of the single-chain antibody gene by a PCR-
based technique [19]. The complete construct containing the nucleotide
sequences encoding the pelB leader peptide, VH domain, (Gly4Ser)3
linker peptide, and VL domain was cloned into the pET3K(x) vector
under the control of T7 RNA polymerase promoter [20].
2.4. Expression of scF11
E. coli BL21(DE3)pLysS cells transformed with the pET(scF11)
plasmid were grown in 1 l of LB broth containing ampicillin (100
mg/l) and chloramphenicol (170 mg/l) at 37‡C until the culture
reached the middle of the log phase. After 2.5^3.0 h of growth, iso-
propyl L-D-thiogalactopyranoside (IPTG) was added to a ¢nal con-
centration of 1 mM and the bacterial cells were grown for additional
4 h at 37‡C. The cells were harvested by centrifugation at 10 000Ug
for 10 min, suspended in 60^80 ml of 50 mM Tris-HCl, pH 8.0,
containing 0.15 M NaCl and 1 mM phenylmethylsulfonyl £uoride
(PMSF), centrifuged as above and washed twice with the same bu¡er.
The cells were resuspended in 60^80 ml of the above bu¡er, disinte-
grated by sonication and centrifuged at 45 000Ug for 20 min. The
sediment of inclusion bodies typically contained scF11 with a purity
of 50^60%.
2.5. Puri¢cation of scF11 and parent F11 antibodies
The pellet of inclusion bodies containing scF11 was solubilized with
6 M guanidine hydrochloride (GdnHCl) in bu¡er A (0.1 M Tris-HCl,
pH 8.0) for 2 h at room temperature. After centrifugation for 45 min
at 40 000Ug, the supernatant was dialyzed against 5 M urea in bu¡er
A containing 1 mM PMSF, then centrifuged to remove precipitated
material and applied on the HiTrapQ anion exchange column
(1.7U2.5 cm). Bound proteins were separated by 0^0.5 M gradient
of NaCl using Pharmacia (Sweden) FPLC system. The protein frac-
tion eluted between 0.2 and 0.3 M NaCl was collected and dialyzed
against 3 M, then 1 M urea in bu¡er A, with centrifugation after
dialyses performed as above. Finally, the protein was dialyzed against
0.05 M sodium phosphate bu¡er, pH 7.5, centrifuged, and used for
further experiments. Typically, the yield of refolded and puri¢ed
scF11 was 10^20 mg from one liter of the cell culture. The parent
mouse monoclonal antiferritin antibody (IgG2a/U) previously de-
scribed as antibody HSF102 [21,22] produced by the F11 hybridoma
cell line, was puri¢ed from ascitic £uid by the procedure of McKiney
and Parkinson [23].
2.6. Human spleen ferritin and [125I]ferritin
Human spleen ferritin was isolated as previously described [21,24].
[125I]Ferritin (speci¢c activity 1.5 Ci/g) was obtained by iodination of
the protein using Iodogen as an oxidant [22].
2.7. Determination of antigen-binding a⁄nity
The antigen-binding a⁄nity was determined both in a direct radio-
immunoassay (RIA) and in a competition enzyme-linked immuno-
sorbent assay (ELISA). The assays were performed at room temper-
ature in triplicates, and the mean values were used for graphic
presentation. Variations in Ka determination were within 25%.
Direct binding RIA was performed as described [22] using strepta-
vidin covalently coupled through protein amino groups to polystyrene
balls (6.3 mm in diameter, the product of the Institute of Physical
Organic Chemistry, Minsk) containing surface-exposed phenaldehyde
groups. The balls were incubated in polystyrene tubes with biotiny-
lated F11 or scF11 (2 Wg/ball), then washed, and increasing concen-
trations of [125I]ferritin were added. After 2 h and washing, bound
[125I]ferritin was quantitated using a Q-counter (RiaGamma, Wallac,
Finland).
In a competition ELISA, polystyrene tubes were coated with rabbit
anti-ferritin IgG by overnight incubation with 3 Wg of IgG in 0.25 ml
of 0.05 M sodium borate, pH 8.5. After 40 min incubation with 1%
BSA and washing, 0.5 mg of human spleen ferritin in 0.25 ml of PBS-
BSA was added. The tubes were incubated for 1.5 h, then washed
twice with distilled water, and 50 ng of biotin-F11 conjugate together
with increasing amounts of F11 or scF11 were added to the tubes in
0.25 ml of PBS-BSA. After 2.5 h and two washings, 250 ng of strep-
tavidin-horseradish peroxidase conjugate were added in 0.25 ml of the
above bu¡er. After another 40 min and washings, 0.6 ml of 0.02 M
o-phenylenediamine and 0.02 M H2O2 in 0.1 M sodium citrate, pH 5,
was added and incubated with shaking for 10 min. The reaction was
stopped by adding 0.2 ml of 10% H2SO4, and absorbance was deter-
mined at 492 nm.
2.8. Fluorescence measurements
Intrinsic and ANS £uorescence spectra were recorded at 25‡C in a
1-cm path length cuvette using SFL-1211 £uorometer (Solar, Belarus)
as described in [25]. Samples for £uorescence measurements were pre-
pared by diluting the protein stock solution to a ¢nal concentration of
0.1 mg/ml in a bu¡er with a required denaturant concentration. The
protein tryptophan £uorescence was excited at 295 nm. The fraction
of scF11 unfolded at increasing denaturant concentrations was calcu-
lated according to [3] from the maximum wavelength of intrinsic
£uorescence. The ANS £uorescence was excited at 360 nm. The ¢nal
ANS-to-protein molar ratios were equal to 20 and 120 for the scF11
and parent F11 antibody, respectively, corresponding approximately
to the ratio of 10 mol of ANS per 1 mol of an antibody domain.
Before recording emission spectra, solutions comprising ANS and the
protein were allowed to equilibrate for 2 h at room temperature; in
the presence of a denaturant, the time required to reach equilibrium
was 16^20 h.
2.9. Other methods
SDS-PAGE was performed according to [26] and stained with Coo-
massie Brilliant Blue R-250. Concentrations of antibodies were deter-
mined from the values of absorption of 0.1% solution in a 1-cm path
length cuvette at 280 nm. The absorption values 1.81 for scF11 and
1.62 for F11 were calculated from the known amino acid sequences
according to [27]. Automatic Edman sequencing of scF11 was per-
formed with Applied Biosystems (USA) protein sequencer, model
470A.
3. Results
3.1. Construction of the scF11-encoding plasmid
To construct the ‘mosaic’ gene of the single-chain antibody,
the four DNA fragments that encode the leader peptide pelB
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(which is responsible for the secretion of the protein into the
periplasm), the heavy chain variable VH domain, the linker
peptide, and the light chain variable VL domain of the mono-
clonal F11 antibody were combined by PCR ampli¢cation of
the DNA ligase products as described in [19]. The gene was
assembled in pUC18 plasmid and at the ¢nal stage was in-
serted into the plasmid pBluescriptsLS(+) containing the uni-
versal translation terminator GCTTAATTAATTAAGC. The
complete gene (Fig. 1) was included in the plasmid pET3K(x)
under the control of T7 RNA polymerase promoter to obtain
a system developed by Studier et al. [20] for expression of
recombinant genes.
3.2. Expression, puri¢cation, refolding
Bacterial expression of scF11 directed by T7 RNA polymer-
ase yielded the amounts of the recombinant protein ranging
from 30 to 50 mg per one liter of the cell culture, as estimated
from SDS-PAGE. The same method showed the lack of pelB
leader sequence in scF11 indicating that the mature protein
was produced, which was further con¢rmed by sequencing the
puri¢ed protein by automatic Edman degradation. The se-
quence of 11 N-terminal amino acids, NH2-Gln-Val-Gln-
Leu-Lys-Gln-Val(Ser)-Gly-Pro-Gly-Leu was in full agreement
with the sequence deduced from the heavy chain cDNA. The
mature antibody was packed in inclusion bodies where scF11
typically constituted 50^60% of the total protein. Solubiliza-
tion with 6 M GdnHCl and subsequent stepwise dialyses,
initially against 5 M urea and then, after ion exchange chro-
matography, against 3 M and 1 M urea, resulted in a signi¢-
cant loss of contaminating proteins (Fig. 2) due to their lower
solubility in comparison with scF11. Also, the HiTrapQ anion
exchange chromatography e⁄ciently removed contaminants
absorbing at 260 nm, presumably nucleic acids. The ¢nal yield
of scF11 was 10^20 mg per 1 l of the cell culture with a purity
more than 95%.
Correct processing of scF11 also assumes proper bonding
of the two expected disul¢des; the absence of additional
bands during SDS-PAGE without L-mercaptoethanol (Fig.
2, tracks 6 and 7) indicated that there were no scF11 dimers
or multimers present in the sample due to formation of inter-
molecular disul¢des. Multi-step refolding by sequential dialy-
sis provided a compact functionally active conformation of
scF11 and prevented drastic losses of the protein. In contrast,
direct dialysis of the antibody preparation dissolved in 5 M
urea against a denaturant-free bu¡er resulted in a massive
precipitation of scF11.
3.3. Binding a⁄nity
The a⁄nity constant, Ka = 5.1U108 M31, determined for
scF11 in direct binding assay using [125I]ferritin, was only
about 8 times purer than Ka of the parent antibody F11
(Fig. 3). Competition ELISA gave approximately 3-fold lower
apparent binding a⁄nities for both the parent antibody and
scF11 resulting in the same ratio of constants as obtained in
RIA.
3.4. Folding of scF11
On decreasing urea concentrations, refolding of puri¢ed
scF11 resulted in an increasing population of species with
Trp £uorophores protected from quenching by the solvent,
as judged by a shift in the maximum emission from 349 nm
in 8 M urea to 337 nm in the refolding bu¡er (Fig. 4A, curve
1). This result suggests that the scF11 antibody reached a
compact tertiary conformation. However, formation of the
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Fig. 2. SDS-PAGE analysis of expression and puri¢cation of scF11:
Coomassie-stained 15% polyacrylamide gel. Tracks: 1: inclusion
bodies solubilized with 6 M GdnHCl; 2, 4, 5: 6 M GdnHCl-solubi-
lized inclusion bodies after dialysis against 5 M, 3 M, and 1 M
urea, respectively; 3: the fraction of inclusion body proteins that
precipitated during dialysis against 5 M urea; 6, 7: puri¢ed scF11
in the presence (6) or absence (7) of L-mercaptoethanol. M: molecu-
lar mass markers: 66 kDa, bovine serum albumin; 45 kDa, ovalbu-
min; 36 kDa, glyceraldehyde-3-phosphate dehydrogenase; 29 kDa,
carbonic anhydrase; 24 kDa, trypsinogen; 20 kDa, soybean trypsin
inhibitor.
Fig. 1. Plasmid pET(scF11) encoding the single-chain antibody
scF11 (upper panel) and the amino acid sequence of scF11 (lower
panel) deduced from the gene. Ampr : ampicillin resistance gene;
prT7: T7 RNA polymerase promoter; pelB: leader peptide sequence
of pectate lyase from Erwinia carotovora ; VH and VL : heavy and
light chain variable domain encoding sequences, respectively. Under-
lined are the pelB leader peptide (double line) and the linker peptide
(G4S)3 (single line).
S.P. Martsev et al./FEBS Letters 441 (1998) 458^462460
¢nal structure of scF11 was accompanied by an increase in
binding of a hydrophobic dye, ANS (Fig. 4A, curve 2), which
is a general feature of partially structured states of proteins
[9,10]. Furthermore, the ¢nal structure of scF11 no longer
displayed an increase in £uorescence intensity on denatur-
ant-induced unfolding as did the completely folded parent
F11 (data not shown). Prominent ANS binding to scF11 ob-
served under physiological conditions was similar to that
shown for the partially structured state of the parent F11
antibody at pH 2 (Fig. 4B). This enhanced binding of ANS
to scF11 might result from either the exposure of domain
interfaces (that are normally masked by partner domains,
CL and CH1, in full-length antibodies) or a £uctuating tertiary
structure characteristic of a partially structured state with
non-native tertiary interactions. The ¢rst possibility is unlikely
since the VL domain of the same antibody which was ex-
pressed, puri¢ed, and refolded to a compact functional con-
formation (Matrsev, Vlasov and Arosio, manuscript in prep-
aration) did not display binding of ANS at pH 7 (data not
shown). Thus, one may conclude that high ANS binding re-
sults from the incomplete tertiary fold of the scF11 antibody.
In terms of the [D]05 values (denaturant concentrations that
provide half-maximal unfolding), stability of scF11 (Fig. 4C)
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Fig. 4. Fluorescence study of folding and stability of scF11. A:
Folding of scF11 monitored by the emission maximum of intrinsic
protein £uorescence (1) and by the emission maximum of protein-
bound ANS. Stock solution of scF11 (2 mg/ml in 8 M urea) was di-
luted 100-fold with 0.05 M sodium phosphate, pH 7, containing
variable urea concentrations. B: Fluorescence spectra of ANS in the
presence of the following proteins: 1, unfolded scF11 (7 M
GdnHCl); 2, unfolded F11 (7 M GdnHCl); 3, parent F11 (pH 7);
4, partly unfolded F11 (pH 2); 5, scF11 after refolding (pH 7). C:
GdnHCl (1) and urea (2) induced unfolding of scF11 at pH 7. The
fraction of the unfolded protein was determined from the maximum
wavelength of intrinsic protein £uorescence, measured as a function
of the denaturant concentration.
Fig. 3. Antigen binding a⁄nity of scF11 in comparison with the pa-
rent antibody as demonstrated by RIA with [125I]ferritin (A) and by
ELISA (B). Insets: Scatchard plot (A) and double reciprocal plot
(B). B and T in panel A: bound and total [125I]ferritin, respectively.
B and B0 in panel B: bound peroxidase activity in the presence and
absence of the competitor, respectively.
S.P. Martsev et al./FEBS Letters 441 (1998) 458^462 461
was similar to that previously observed for several scFv pro-
teins. These values for scF11 (4.5 M urea, or 2.5 M GdnHCl,
Fig. 4C) are close to or even higher than those reported for
other single-chain antibodies (1.0 M GdnHCl or 3.7 M urea
[3,28], 4.1 M urea [29], 2.0 M urea [30]). However, scF11
demonstrated low stability against aggregation, which resulted
in precipitation of 30^50% of the protein after two weeks at
2^4‡C.
4. Discussion
A remarkable feature of the engineered scF11 antibody
after its expression, puri¢cation and refolding is the ability
to bind a hydrophobic dye, ANS, in the physiological solvent
conditions. The enhanced ANS-binding capacity of a protein
is one of the generally accepted criteria of incomplete folding
with £uctuating tertiary structure that allows the dye to gain
access to the hydrophobic core [9,10]. Therefore, prominent
binding of ANS to the antiferritin scF11 antibody suggests
incomplete folding of this protein. Nevertheless, the antigen-
binding a⁄nity of scF11 was only V8-fold lower than that of
the parent F11 antibody. This ¢nding indicates that a dis-
torted tertiary structure of scF11 does not destroy the struc-
tural integrity of the antigen-combining site. These results
partially contradict the generally accepted concept that the
protein functionality is tightly associated with a completely
folded conformation.
Until now, the ANS-binding capacity of the single-chain
antibodies has not been reported, and therefore it remains
to be shown whether or not this property is general for
scFv proteins. However, there are at least three general fea-
tures of scF11 and single-chain antibodies described previ-
ously, the ¢rst of them being a prominent tendency to aggre-
gation. This property may be attributed to either transient
exposure of the hydrophobic interior of the protein, or to
the linker peptide. The other general features of scFv proteins
are their relatively low stability and apparently two-state tran-
sition observed on denaturant-induced unfolding. The latter
property might equally result from either strong domain in-
teractions with tightly-associated folding of the two domains
or, alternatively, from weak, if any, interactions between do-
mains with closely similar transition parameters [3,5,31].
Based on the similarity of features related to folding and
stability of single-chain antibodies, one can assume that the
antiferritin antibody scF11 is not unique with regard to the
observed folding parameters. To verify this assumption, ex-
tended folding/stability studies should be carried out using a
series of single-chain antibody constructs.
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